Publications

View and download slide summaries of the latest original articles focusing on therapies in immune-mediated inflammatory diseases including rheumatology, dermatology, and gastroenterology. All materials produced by the team are subsequently reviewed and approved by individual Steering Committee members.

November 2025

A retrospective observational study of effectiveness of sequential biologic and targeted synthetic DMARDs in psoriatic arthritis in the UK

Rheumatology 2025 Doi: 10.1093/rheumatology/keaf570 Epub ahead of print

Smith T,

Fahy C,

and the SEQUENCE Study Group

Gollins et al. reported that within this cohort, the Psoriatic arthritis response criteria (PsARC) response to 4^th+ lines of b/tsDMARD was not significantly reduced compared with 2^nd/3^rd line in participants who had failed at least 3 b/tsDMARDs. Authors evaluated the primary clinical response to sequential lines of b/tsDMARD therapy in PsA, focusing on the effectiveness of later line treatments.

Keywords:

March 2025

Achievement of endoscopic remission after induction reduces hospitalization burden in Crohn’s Disease: findings from a pooled post hoc analysis of risankizumab and upadacitinib Phase III trials

J Crohns Colitis. 2025 Feb 4;19(2):jjae128. doi: 10.1093/ecco-jcc/jjae128.

Panaccione R,

Ma C,

Jairath V,

Dignass A,

Joshi N,

Clark R,

Smith Z,

Nunag D,

Panaccione et al. investigated the association between achievement of endoscopic remission following induction therapy and hospitalisation outcomes in Crohn’s disease. Patients achieving endoscopic remission at Week 12 experienced a 55% reduction in Crohn’s disease-related hospitalisation rates over the 52-week maintenance period. The results support endoscopic remission as an early therapeutic target.